These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 12238451)
21. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204 [TBL] [Abstract][Full Text] [Related]
22. [First nucleotide analog with noteworthy safety profile. Tenofovir effective in all stages of the infection]. MMW Fortschr Med; 2003 Apr; 145 Spec No 1():62-4. PubMed ID: 15011594 [No Abstract] [Full Text] [Related]
23. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy]. MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158 [No Abstract] [Full Text] [Related]
24. [Nucleotide analog shows effectiveness in previously treated patients. The new kind of HAART]. MMW Fortschr Med; 2002 Apr; 144 Suppl 1():62-4. PubMed ID: 12043078 [No Abstract] [Full Text] [Related]
25. [96-week treatment outcome confirms long term efficacy of tenofovir DF]. Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796 [No Abstract] [Full Text] [Related]
34. Use of tenofovir. AIDS Patient Care STDS; 2002 Jan; 16(1):52. PubMed ID: 11892609 [No Abstract] [Full Text] [Related]
35. [Resistance in a new light. About mutations and their interactions]. MMW Fortschr Med; 2003 Apr; 145 Spec No 1():64-5. PubMed ID: 15011595 [No Abstract] [Full Text] [Related]
36. [First nucleotide analog against HIV. Lowers viral load also in drug resistance]. MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157 [No Abstract] [Full Text] [Related]
37. Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus. Van Rompay KK; Schmidt KA; Lawson JR; Singh R; Bischofberger N; Marthas ML J Infect Dis; 2002 Nov; 186(10):1508-13. PubMed ID: 12404171 [TBL] [Abstract][Full Text] [Related]
38. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Murphy MD; O'Hearn M; Chou S Clin Infect Dis; 2003 Apr; 36(8):1082-5. PubMed ID: 12684925 [TBL] [Abstract][Full Text] [Related]
39. Tenofovir DF trial announced by Gilead. Eagan L Posit Living; 2000 Jul; 9(6):22, 54. PubMed ID: 12492018 [No Abstract] [Full Text] [Related]
40. FDA approves tenofovir. AIDS Patient Care STDS; 2002 Jan; 16(1):52. PubMed ID: 11892608 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]